Platinum-Based Chemotherapy in Metastatic Prostate Cancer With DNA Repair Gene Alterations

Abstract

Patients with DDRmut disease had better response to platinum-based chemotherapy, suggesting that DDR status warrants prospective validation as a potential biomarker for patient selection. Responses to platinum chemotherapy were observed in <i>BRCA</i>-altered prostate cancer after PARPi progression. Additional studies are needed to determine the predictive role of individual genes on platinum sensitivity in the context of other clinical and genomic factors.